FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2018/04/013462 [Registered on: 24/04/2018] Trial Registered Retrospectively
Last Modified On: 13/04/2018
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug 
Study Design  Randomized, Parallel Group, Placebo Controlled Trial 
Public Title of Study   Study to compare the effect of a medicine (lignocaine) given by two ways,first one is by vapour (nebulisation)and second by injection into the blood to reduce the blood pressure and heart rate changes during the procedure of passing the tube into the wind pipe(trachea) tube to wind pipe 
Scientific Title of Study   Comparison between intravenous and nebulised lignocaine for haemodynamic response to laryngoscopy and intubation 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Kiran R Asranna 
Designation  junior resident 
Affiliation  KMC Manipal 
Address  Department of Anaesthesiology CSOT Block Kasturba Hospital Manipal University Manipal
Room no. 423, NBQ Hostel, KMC campus, Manipal
Udupi
KARNATAKA
576104
India 
Phone  9986373248  
Fax    
Email  kirz92cool@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Kiran R Asranna 
Designation  Junior Resident 
Affiliation  KMC Manipal 
Address  Department of Anaesthesiology CSOT Block Kasturba Hospital Manipal University Manipal
Room no. 423 NBQ Hostel KMC Campus, Manipal
Udupi
KARNATAKA
576104
India 
Phone  9986373248  
Fax    
Email  kirz92cool@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Shaji Mathew 
Designation  Associate Professor 
Affiliation  KMC Manipal 
Address  Department of anaesthesiology CSOT Block Kasturba Hospital Manipal University Manipal
NBQ hostel, Kmc campus, Manipal
Udupi
KARNATAKA
576104
India 
Phone  9964620729  
Fax    
Email  shajimanipal@yahoo.co.in  
 
Source of Monetary or Material Support  
Manipal Academy of Higher Education, Kasturba College and Hospital, Manipal, Udupi, Karnataka  
 
Primary Sponsor  
Name  Kasturba Medical College PG thesis fund 
Address  Kasturba medical college, Manipal Academy of Higher Education,Manipal,Udupi,Karnataka 
Type of Sponsor  Private medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Kiran R  Kasturba Medical College and Hospital,Manipal  Department of Anesthesia Manipal Academy of Higher Education, Kasturba College and Hospital, Manipal.
Udupi
KARNATAKA 
9986373248

kirz92cool@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
KASTURBA MEDICAL COLLEGE AND KASTURBA HOSPITAL-INSTITUTIONAL ETHICS COMMITTEE  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  Age group between 18 and 65years of either gender belonging to ASAPS 1 undergoing any surgery under general anaesthesia with endotracheal intubation.,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Group C  Control group 
Intervention  Group I  Group I receives 1.5 mg/kg of preservative free 2% lignocaine intravenously 90 seconds before laryngoscopy 
Intervention  Group N  Group N receives 5ml of 4% Nebulised lignocaine 15 to 20 minutes before laryngoscopy 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  Elective surgical procedures under general anaesthesia requiring endotracheal intubation
Age between 18 to 60 years age of either gender
Modified Mallampati class I & II
ASA PS I
 
 
ExclusionCriteria 
Details  1. Anticipated difficult airway
2. Baseline heart rate < 50 bpm
3. At risk for gastric aspiration
4. BMI > 30 kg/m2
5. Known allergy to lignocaine

 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Participant Blinded 
Primary Outcome  
Outcome  TimePoints 
hemodynamic response
1)Heart rate
2)Mean arterial pressure 
1- Baseline value
2- Just before laryngoscopy
3- Immediately after laryngoscopy and intubation
4- Every minute after laryngoscopy and intubation for the first 5 minutes

 
 
Secondary Outcome  
Outcome  TimePoints 
Duration of laryngoscopy  Should not exceed 15 seconds 
 
Target Sample Size   Total Sample Size="66"
Sample Size from India="66" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 2/ Phase 3 
Date of First Enrollment (India)   20/02/2017 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details   Not published 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Brief Summary  

Several studies have been made in order to attenuate these haemodynamic response to laryngoscopy and intubation. Many drugs also have been used for the same purpose [3]. The techniques include topical anaesthesia of oropharynx (viscous lignocaine) laryngotracheal instillation of lignocaine just prior to intubation, intravenous lignocaine, adrenergic blocking drugs, (either alpha or beta blockers) vasodilators like hydrallazine, sodium nitroprusside, nitroglycerine, deep inhalational anaesthesia, intravenous opioids etc., No single agent has been established as the most Anaesthesia Section appropriate for this purpose. Among the recommended procedures, intravenous lidocaine or fentanyl appear to best fulfill the above mentioned criteria [2]. Lignocaine is a amide (-NHCO-) synthetic local anaesthetic. The use of lignocaine is well known in treatment of patients with ventricular dysarrthmias and as prophylaxis in treatment of ventricular tachyarrthmias especially in connection with myocardial infarction and mechanical irritation of cardia. The principal metabolic pathway of lignocaine is oxidative dealkalysation in the liver to monoethylglylcinexylidide followed by hydrolysis of this metabolite to xylidide. Monoethylglycinexylidide has approximately 80% of the activity of lignocaine for protection against cardiac dysarrythmias. Lignocaine prevents transmission of nerve impulse (conduction blockade) by inhibiting passage of sodium ions through ion selective sodium channels in nerve membrane [4]. The sodium channel itself is a specific receptor to lignocaine molecule. Fentanyl is a potent, synthetic narcotic analgesic with a rapid onset and short duration of action. It is extremely lipid soluble, has a low molecular weight and is a synthetic opioid agonist which is popularly used as intravenous analgesic supplement, component of inhalation anaesthesia, balanced anaesthesia and neurolept analgesia and also as a sole anaesthetic. It is 75 to 125 times more potent than morphine as an analgesic [5]. After intravenous administration, onset of effect is 1-2 minutes, and the duration is 1 hour. Consequently it has proved ideal for control of the short lived haemodynamic sequelae, associated with laryngoscopy and intubation.

Some studies note a response of intravenous lignocaine in blunt-ing rises in pulse, blood pressure, intracranial and intraocular pressure. Studies have discussed the possible mechanisms to account for these observations with IV lignocaine. These include a direct myocardial depressant effect, a peripheral vasodilating effect and finally an effect on synaptic transmission [8]. A review on “Prophylactic lidocaine use preintubation”. They said that a dose of prophylactic lidocaine of 1.5 mg/kg given intravenously 3 minutes before intubation is optimal. No studies document any harmful effects of prophylactic lidocaine given preintubation [15]. Wang et al., [16] reported most optimal time of administration of intravenous lidocaine to attenuate the increase of intraocular pressure seemed to be the space between 1-3 minutes before laryngoscopy and tracheal intubation. Wilson et al., [17] showed that irrespective of the timing of administration of injection of lignocaine 2, 3 or 4 minutes before tracheal intubation, there was a significant increase in heart rate of 21-26% in all groups. There was no significant increase in mean artrial pressure (MAP) in response to intubation in any group of patients given lignocaine before intubation, but in the placebo group, MAP increased by 19% compared to baseline values. Mollick et al., [18] observed that intravenous lignocaine with pethidine did attenuate the sympathetic responses to laryngoscopy and endotracheal intubation which came down to base line before 5 minute after intubation. But the group of patients which was treated only with lignocaine, their sympathetic responses did not come down to base line at 5 minute after laryngoscopy and endotracheal intubation. Similar to our observation Bachofen M [2] too reported that fentanyl showed a significant pressure-lowering action persisting over the whole observation period in all patients while no significant effect of lidocaine on the pressure response could be observed. Malde and Sarode [19] concluded that “ given 5 minutes prior to intubation, lignocaine (1.5 mg/kg) and fentanyl (2 µg/kg) both attenuated the rise in pulse rate, though fentanyl was better. 

 
Close